- Correlate laboratory prognostic factors for large cell lymphoma with clinical response
to this regimen.

OUTLINE: This is a multicenter study.

Patients receive epratuzumab IV over 1 hour on day 1, rituximab IV over 4-8 hours on day 1
or days 1 and 2, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine IV on
day 1 or 2, and oral prednisone on days 1-5 or 2-6. Treatment repeats every 21 days for up
to 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically for up to 5 years.

PROJECTED ACCRUAL: A total of 86 patients will be accrued for this study.

- AST ≤ 3 times upper limit of normal (ULN) (5 times ULN if there is liver involvement)

- Creatinine ≤ 2 times ULN

- Life expectancy ≥ 12 weeks

- Negative pregnancy test

- Not pregnant or nursing

- Fertile patients must use effective contraception during and for 12 months after
completion of study treatment

- No active serious infection requiring antibiotics

- No New York Heart Association class III or IV heart disease

- No other primary malignancy within the past 5 years, except for squamous cell or
basal cell carcinoma of the skin, in situ carcinoma of the cervix, or previously
treated prostate cancer with a stable prostate-specific antigen

- No known HIV positivity

- No known hepatitis B or C infection

- Ejection fraction ≥ 45% by MUGA or echocardiogram (required if patients has a history
of heart disease or is ≥ 50 years old)

- Willing to provide blood and tissue samples for mandatory translational research
component of study

PRIOR CONCURRENT THERAPY:

- No prior therapy for diffuse large B-cell lymphoma, including the following:

We are a Cancer Social Network, Resource Directory & Education Hub supporting all those affected by cancer. knowcancer.com is intended to be solely for informational purposes and should not be a substitute for professional medical advice, diagnosis or treatment.